Evidence map›Paper›PMID 26307193›Full record

ArticleExpert opinion on drug delivery2016

Discovery of a new method for potent drug development using power function of stoichiometry of homomeric biocomplexes or biological nanomotors.

Fengmei Pi, Mario Vieweger, Zhengyi Zhao, Shaoying Wang, Peixuan Guo

Abstract read
In one paragraph

Article in Expert opinion on drug delivery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fengmei Pia 1 University of Kentucky, Nanobiotechnology Center , Lexington, KY 40536, USA.
Mario Viewegera 1 University of Kentucky, Nanobiotechnology Center , Lexington, KY 40536, USA.
Zhengyi Zhaoa 1 University of Kentucky, Nanobiotechnology Center , Lexington, KY 40536, USA.
Shaoying Wanga 1 University of Kentucky, Nanobiotechnology Center , Lexington, KY 40536, USA.
Peixuan Guoa 1 University of Kentucky, Nanobiotechnology Center , Lexington, KY 40536, USA.

Funding

Phi29 Motor Nanopore for Single Molecule Sensing and dsDNA FingerprintingR01EB012135 · NIBIB · UNIVERSITY OF KENTUCKY · PI GUO, PEIXUAN · 2011 to 2019
$2.6M
RNA Nanotechnology in Cancer TherapyU01CA151648 · NCI · UNIVERSITY OF KENTUCKY · PI GUO, PEIXUAN, LI, HENRY · 2010 to 2014
$2.1M
NCI NIH HHS U01 CA151648NIBIB NIH HHS R01 EB012135
6 · The paper itself

Abstract

introductionMultidrug resistance and the appearance of incurable diseases inspire the quest for potent therapeutics. AREAS COVERED: We review a new methodology in designing potent drugs by targeting multi-subunit homomeric biological motors, machines or complexes with Z > 1 and K = 1, where Z is the stoichiometry of the target, and K is the number of drugged subunits required to block the function of the complex. The condition is similar to a series electrical circuit of Christmas decorations: failure of one light bulb causes the entire lighting system to lose power. In most multi-subunit, homomeric biological systems, a sequential coordination or cooperative action mechanism is utilized, thus K equals 1. Drug inhibition depends on the ratio of drugged to non-drugged complexes. When K = 1, and Z > 1, the inhibition effect follows a power law with respect to Z, leading to enhanced drug potency. The hypothesis that the potency of drug inhibition depends on the stoichiometry of the targeted biological complexes was recently quantified by Yang-Hui's Triangle (or binomial distribution), and proved using a highly sensitive in vitro phi29 viral DNA packaging system. Examples of targeting homomeric bio-complexes with high stoichiometry for potent drug discovery are discussed. EXPERT OPINION: Biomotors with multiple subunits are widespread in viruses, bacteria and cells, making this approach generally applicable in the development of inhibition drugs with high efficiency.

Indexed as

Drug DesignDrug DiscoveryHumansTechnology, Pharmaceuticalantibacterialantivirusbinomial distributioncancer drug developmentdrug developmentdrug targethexameric ATPasephi29 dsDNA packaging motorviral assembly

Identifiers

PMID26307193
PMCPMC4713257

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.